Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from AbCellera Biologics Inc.’s reported figures.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s EBIT?
- AbCellera Biologics Inc. (ABCL) reported EBIT of -$62.78M in Q2 2026.
- How has AbCellera Biologics Inc.'s EBIT changed year-over-year?
- AbCellera Biologics Inc.'s EBIT decreased by 26.6% year-over-year, from -$49.59M to -$62.78M.
- What is the long-term trend for AbCellera Biologics Inc.'s EBIT?
- Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s EBIT has grown at a 2.0% compound annual growth rate (CAGR), from $204.5M to -$217.11M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about AbCellera Biologics Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude